Suven Pharmaceuticals is all set to acquire a controlling stake in NJ Bio Inc. (NJ Bio) with an investment of $64.4 million. Based in Princeton, NJ Bio is a premier ADC/XDC-focused CRDMO offering cutting-edge solutions across the ADC value chain.
This acquisition positions the company as a key player in one of the fastest growing segments of the Pharma CDMO landscape and it also extends the company’s current ADC offering with expertise across payload chemistry, payload-linker synthesis, bioconjugation, and AD specific analytical platform. The transaction is expected to close before the end of December 2024.
Suven Pharmaceuticals is India’s leading technology-focused CDMO, offering integrated solutions in custom synthesis, process R&D, and manufacturing for global innovators.
